Can Bloodwork Detect Colon Cancer? | The Screening Limits

Bloodwork alone cannot diagnose colon cancer, but certain blood-based biomarker tests can screen for it by detecting tumor DNA or proteins.

You’ve probably heard the idea that a simple blood draw could catch colon cancer early. It makes sense — blood tests check for so many things. The catch: diagnosing colon cancer requires looking directly at the colon lining, which bloodwork can’t do.

So when people ask about bloodwork to detect colon cancer, the answer comes down to what kind of blood test you mean. Routine panels offer hints. Newer biomarker tests screen for the disease. Neither replaces a colonoscopy or stool-based test for a clear answer.

What Bloodwork Can and Can’t Tell You

Standard blood tests — a complete blood count (CBC) or metabolic panel — aren’t designed to find cancer cells. What they can do is flag changes that sometimes accompany colon cancer. Studies show people with colorectal cancer tend to have lower red blood cell levels within a year of diagnosis compared to those without the disease. That might hint at bleeding tumors.

Liver and kidney function numbers on a metabolic panel can also shift if cancer has spread. But these are clues, not proof. Mayo Clinic explains that blood tests are not used to diagnose colon cancer, though they give useful health snapshots.

Blood-based biomarker screening tests are a different story. These look for tiny bits of tumor DNA or specific proteins circulating in your bloodstream. Medicare covers one such test every three years for eligible beneficiaries, calling it an appropriate screening option. Still, the American Cancer Society emphasizes that tumor markers cannot be used alone to screen or diagnose.

Why The “Simple Blood Test” Myth Sticks

It’s easy to wish for a needle stick instead of a colonoscopy prep. That hope drives interest in blood-based screening. But the reality is more layered. Here’s what the research actually shows:

• Precancerous polyp detection is poor: Blood-based screening has essentially no ability to detect advanced precancerous polyps beyond chance discovery — about 13%. That means most worrisome polyps get missed.
• Late-stage cancers are easier to spot: An investigational blood test was effective at identifying existing tumors but much less effective at finding precancerous polyps. The same pattern holds for the FDA-approved Guardant Shield test.
• CEA is not a screening tool: Carcinoembryonic antigen (CEA) levels rise in some colon cancers, but its sensitivity in average-risk populations is far too low. Experts say it has no role as a screening test.
• False reassurance is real: Because blood tests miss many early cancers and almost all precancerous polyps, a normal result can give a dangerous sense of security. A normal CEA does not rule out colon cancer.
• No single blood test is a stand-alone solution: All major medical groups recommend blood-based screening only when other methods aren’t available or acceptable, not as a first choice.

Understanding CEA and Other Tumor Markers

CEA is the most discussed blood marker for colon cancer, but it’s mostly used after diagnosis — to monitor treatment response or check for recurrence. For average-risk adults, the test is not useful because too many factors can raise CEA without cancer: smoking, pancreatitis, inflammatory bowel disease, and even some benign liver conditions.

Normal CEA levels are generally between 0 and 3 ng/mL, with slight variations by lab. But even that range doesn’t guarantee safety. Research from the NIH shows that no threshold level for CEA gives enough sensitivity and specificity to allow it to be used alone for recurrence detection, let alone initial screening. The blood tests not used section of Mayo Clinic’s colon cancer guide makes this distinction clear: tumor markers are not diagnostic tools.

Other markers like CA 19-9 and circulating tumor DNA (ctDNA) are being studied, but none have earned FDA approval for routine screening in average-risk people beyond the Guardant Shield blood test, which is recommended every three years.

Each method has trade-offs. Blood tests offer convenience but miss the majority of precancerous polyps, which is why they’re not a first-choice screening for most people.

The New FDA-Approved Blood Test: What It Can and Can’t Do

In 2024, the FDA approved Guardant Shield as the first blood-based colorectal cancer screening test for average-risk adults aged 45 and older. It detects circulating tumor DNA from colorectal tumors. The American Gastroenterological Association gives it guarded endorsement, recommending it every three years for people who decline colonoscopy or other recommended tests.

Here’s the honest trade-off: The test is relatively good at finding later-stage cancers but much weaker at early-stage cancers and precancerous polyps. UT Southwestern Medical Center notes the FDA-approved blood test detects later-stage cancers more reliably, yet its ability to catch the earliest, most treatable changes is limited. That means you could get a “normal” result while a precancerous polyp is already growing.

CEA levels can also be misleading. Normal ranges vary by smoking status — CEA levels in smokers tend to run higher, with some patient communities noting up to 5 ng/mL as normal for smokers. A slightly elevated CEA may trigger unnecessary worry, while a normal level may offer false comfort. For these reasons, expert guidance stresses that blood-based tests work best when paired with other screening methods, not used alone.

The Bottom Line

Bloodwork plays a supporting role in colon cancer detection but can’t replace direct visualization of the colon. Routine labs may flag warning signs like unexplained anemia. Newer biomarker tests offer a convenient screening option for people who can’t or won’t undergo colonoscopy, with the understanding that they miss most precancerous polyps. If a blood test suggests possible cancer, colonoscopy is still the definitive next step.

For people at average risk starting at age 45, the choice between colonoscopy, stool tests, and blood-based screening is best made with your primary care doctor or a gastroenterologist, who can factor in your personal risk, family history, and the limits of each option.